Top

Current Clinical Trials

Let us know you are interested in participating in one of the Actively Recruiting Clinical Trials:

Actively Recruiting

◊ A Prospective Randomized Placebo-Controlled Double-Blind Study Assessing Change in Olfactory Function After Initiation of Rasagiline in Idiopathic Parkinson's Disease (PD-SOAR)

◊ A Randomized, Placebo-Controlled, Multi-Center Study to Assess the Disease Modifying Potential of Transdermal NICotine in Early Parkinson's Disease in Germany and the USA (NIC-PD)

◊ The Parkinson’s Progression Markers Initiative (PPMI)

 ◊ A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Rotigotine on Motor Symptoms in Patients with Advanced Parkinson’s Disease with Motor Fluctuations and Gastroparesis (ROADMAP; SP1055)

 ◊ A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain (DOLORES; PD0004)

Ongoing, But Not Actively Recruiting:
◊ 13-Week, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-Dopa Induced Dyskinesias in Patients with Parkinson’s Disease (CAFQ056A2223)
◊ A Longitudinal Observational Follow-up of the PRECEPT Study Cohort (PostCEPT)
◊ A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects with Treated Parkinson's Disease. Long-term Study - 1 (NET-PD LS-1)
◊ A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease (ACP-103-015)
◊ An Open-Label Conversion Study of Carbidopa-Levodopa Extended-Release (CD-LD ER) Taken Alone or in Combination with Carbidopa-Levodopa Immediate Release (IR) to IPX066 Followed by an Open-LabelExtension Safety Study of IPX066 in Subjects with Advanced Parkinson’s Disease (IPX066-B11-01)
◊ An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study (TVP-1012/501)
◊ An Open-Label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson’s Patients with L-Dopa Induced Dyskinesias (CAFQ056A2217)
◊ An Open-Label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson’s Patients with L-Dopa Induced Dyskinesias (CAFQ056A2299)
◊ A Phase 3, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease (P07037)
◊ A Phase 3, 40-Week, Active-Controlled, Double-Blind Double Dummy Extension Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease (P06153)
◊ National Parkinson Foundation Quality Improvement Initiative (NPF-QII)
◊ Parkinson Associated Risk Factor Study (PARS):  Evaluating Potential Screening Tools for Parkinson Disease


clientuploads/home_npf.jpg

675 Almanor Avenue | Sunnyvale, CA 94085
408.734.2800 main | 408.734.8455 fax (Main) | 408.734.9208 fax (Clinic Secure)
Copyright © 2013 The Parkinson's Institute and Clinical Center